Newlink Genetics Corp (NLNK) 38.84 $NLNK
Novavax starts early stage Ebola vaccine trial
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 12:18PM CST
JNJ: 99.62 (+1.18), NVAX: 8.80 (+0.40), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), GSK: 47.94 (+1.99)
U.S. to pull troops from Ebola zone
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:38AM CST
INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99)
Did Researchers Just Discover the Cause of Pancreatic Cancer?
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 31, 11:23AM CST
Source: Flickr user Sunil Joshi. Although no cancer diagnosis is welcome, perhaps no cancer type comes with a more frightening outlook than pancreatic cancer. According to data from the American Cancer Society, pancreatic cancer is the twelfth...
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30), PFE: 34.64 (-0.23), NLNK: 38.84 (+1.51), THLD: 4.03 (+0.21), CELG: 115.88 (+0.16)
TrovaGene Partners with Leading Cancer Research Institutes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 11:00AM CST
TrovaGene Inc. (TROV) recently announced a number of collaborations with eminent research institutes around the world.
TROV: 4.99 (-0.17), NLNK: 38.84 (+1.51), AMGN: 153.48 (+0.30), CELG: 115.88 (+0.16)
Illumina Launches MiSeq FGx for Forensic DNA Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 4:50PM CST
Illumina's (ILMN) MiSeq FGx system will not only play a crucial role in solving criminal caseworks but also hold immense value in other unusual situations like mass disasters, missing persons, and unidentified human remains.
NLNK: 38.84 (+1.51), ALXN: 182.29 (+6.02), ILMN: 198.54 (+1.81), FPRX: 24.63 (+0.63)
Morning Analysis on Biotech Stocks -- Novavax, Isis Pharma, OPKO Health, Nanosphere, and NewLink Genetics
PR Newswire - Tue Jan 20, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Novavax Inc. (NASDAQ: NVAX), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), OPKO Health Inc. (NYSE: OPK), Nanosphere Inc. (NASDAQ: NSPH), and NewLink Genetics Corporation (NASDAQ: NLNK). Free research reports can be accessed at the links given below. On Friday, January 16, 2015, the NASDAQ Composite ended at 4,634.38, up 1.39%, the Dow Jones Industrial Average advanced 1.10%, to finish the day at 17,511.57, and the S&P 500 closed at 2,019.42, up 1.34%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 814.62, up 1.92%, with the index also advancing 15.08% in the previous three months. Register for your complimentary reports at the links given below.
ISIS: 63.86 (-0.43), OPK: 13.80 (-0.28), NVAX: 8.80 (+0.40), NLNK: 38.84 (+1.51), NSPH: 0.25 (unch)
Johnson & Johnson announces Ebola vaccine development consortia
Seeking Alpha - at Seeking Alpha - Fri Jan 16, 7:54AM CST
JNJ: 99.62 (+1.18), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), GSK: 47.94 (+1.99)
Critical Alerts For Ford, BlackBerry, Aegerion Pharmaceuticals, Yahoo! and NewLink Genetics Released By InvestorsObserver
PR Newswire - Thu Jan 15, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for F, BBRY, AEGR, YHOO and NLNK.
YHOO: 44.42 (+0.50), F: 16.30 (-0.06), BBRY: 10.09 (+0.23), NLNK: 38.84 (+1.51), AEGR: 25.15 (+0.88)
Affymetrix (AFFX) Expands Genotyping Arrays Product Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 12:10PM CST
Provider of life science tools and molecular diagnostic products, Affymetrix, Inc. (AFFX), is expected to highlight various new genotyping arrays at the 2015 Plant and Animal Genome Conference.
NLNK: 38.84 (+1.51), ALXN: 182.29 (+6.02), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
Biotech Weekly: Lessons Learned From Investing In Ebola Stocks
Daniel Ward - at Seeking Alpha - Mon Jan 12, 7:38AM CST
HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), IBIO: 0.90 (+0.36)
InsiderInsights.com Daily Round Up 1/8/15: CPRX, HCOM, RPXC, ARIS
InsiderInsights - at Seeking Alpha - Sat Jan 10, 2:07AM CST
RH: 86.77 (-1.55), MNST: 117.74 (-1.77), HCOM: 26.76 (-0.10), SPE: 15.27 (+0.02), PGEM: 13.79 (+0.24), ARIS: 3.63 (-0.01), FUND: 7.47 (+0.05), RPXC: 13.94 (+0.42), CMC: 15.40 (+0.37), LNKD: 269.00 (+1.83), PFPT: 55.97 (+0.38), CPRX: 3.36 (-0.10), REN: 1.14 (unch), NERV: 4.68 (+0.09), NLNK: 38.84 (+1.51), CPLA: 65.23 (-1.37), WYY: 1.50 (+0.02), ESP: 29.25 (+2.53)
Biogen Reveals Positive Data from Acute Optic Neuritis Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 4:35PM CST
Biogen Idec (BIIB) announced positive top-line results from a phase II study on anti-LINGO-1 for the treatment of patients suffering from acute optic neuritis.
BIIB: 391.66 (-0.45), NLNK: 38.84 (+1.51), AMAG: 41.49 (+0.23), RGDO: 1.17 (+0.02)
Biotech Investors Guide and Preview to the J.P. Morgan Healthcare Conference Part 2
at The Street - Fri Jan 09, 6:40AM CST
The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.
NLNK: 38.84 (+1.51), JUNO: 40.52 (+0.18), EXAS: 25.56 (-0.54), ABBV: 58.05 (+1.00), MNKD: 7.00 (+0.02)
NewLink Genetics to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 07, 4:00PM CST
NewLink Genetics Corporation (Nasdaq:NLNK) today announced that Charles J. Link, Jr., M.D., NewLink's Founder and Chief Executive Officer, is scheduled to present at the 33 Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 14, 2015 at 4:00 p.m. PT. The presentation will not be webcast.
JPM: 59.67 (+0.10), NLNK: 38.84 (+1.51)
Scotland confirms Ebola case
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 12:53AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22)
NewLink and Merck Get a $30M Contract for Ebola Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 11:00AM CST
NewLink Genetics and Merck announced that the BARDA has awarded a $30 million contract for their Ebola vaccine candidate, rVSV-EBOV.
MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), GSK: 47.94 (+1.99)
Viral Investing: Ebola Drug Makers' Varied Strategies
at Investor's Business Daily - Fri Dec 26, 3:09PM CST
The stock market is an organism that strives to identify opportunity in every crisis. That held true in the late summer and early fall, when the outbreak of Ebola virus in West Africa reached crisis proportions in Guinea, Liberia and Sierra Leone....
BBP: 28.36 (+0.12), INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BBC: 28.98 (+0.18), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), MRK: 58.81 (-0.07), SRPT: 12.76 (+0.11), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), GSK: 47.94 (+1.99)
BARDA awards Ebola vaccine contract to NewLink Genetics
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 7:44AM CST
MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51)
NewLink Genetics, Merck Collaboration to Manufacture Ebola Vaccine Candidate Supported by $30 Million Government Award
GlobeNewswire - Mon Dec 22, 7:00AM CST
NewLink Genetics Corporation (Nasdaq:NLNK) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) has awarded NewLink Genetics' wholly-owned subsidiary, BioProtection Systems, as the prime contractor in a $30 million contract to support the manufacturing and development activities of its investigational rVSV-EBOV (Ebola) vaccine candidate, including clinical development through a new 330-person Phase Ib study.
MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51)
Novavax starts early stage Ebola vaccine trial
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 12:18PM CST
JNJ: 99.62 (+1.18), NVAX: 8.80 (+0.40), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), GSK: 47.94 (+1.99)
U.S. to pull troops from Ebola zone
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:38AM CST
INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99)
Did Researchers Just Discover the Cause of Pancreatic Cancer?
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 31, 11:23AM CST
Source: Flickr user Sunil Joshi. Although no cancer diagnosis is welcome, perhaps no cancer type comes with a more frightening outlook than pancreatic cancer. According to data from the American Cancer Society, pancreatic cancer is the twelfth...
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30), PFE: 34.64 (-0.23), NLNK: 38.84 (+1.51), THLD: 4.03 (+0.21), CELG: 115.88 (+0.16)
TrovaGene Partners with Leading Cancer Research Institutes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 11:00AM CST
TrovaGene Inc. (TROV) recently announced a number of collaborations with eminent research institutes around the world.
TROV: 4.99 (-0.17), NLNK: 38.84 (+1.51), AMGN: 153.48 (+0.30), CELG: 115.88 (+0.16)
Illumina Launches MiSeq FGx for Forensic DNA Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 4:50PM CST
Illumina's (ILMN) MiSeq FGx system will not only play a crucial role in solving criminal caseworks but also hold immense value in other unusual situations like mass disasters, missing persons, and unidentified human remains.
NLNK: 38.84 (+1.51), ALXN: 182.29 (+6.02), ILMN: 198.54 (+1.81), FPRX: 24.63 (+0.63)
Morning Analysis on Biotech Stocks -- Novavax, Isis Pharma, OPKO Health, Nanosphere, and NewLink Genetics
PR Newswire - Tue Jan 20, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Novavax Inc. (NASDAQ: NVAX), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), OPKO Health Inc. (NYSE: OPK), Nanosphere Inc. (NASDAQ: NSPH), and NewLink Genetics Corporation (NASDAQ: NLNK). Free research reports can be accessed at the links given below. On Friday, January 16, 2015, the NASDAQ Composite ended at 4,634.38, up 1.39%, the Dow Jones Industrial Average advanced 1.10%, to finish the day at 17,511.57, and the S&P 500 closed at 2,019.42, up 1.34%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 814.62, up 1.92%, with the index also advancing 15.08% in the previous three months. Register for your complimentary reports at the links given below.
ISIS: 63.86 (-0.43), OPK: 13.80 (-0.28), NVAX: 8.80 (+0.40), NLNK: 38.84 (+1.51), NSPH: 0.25 (unch)
Johnson & Johnson announces Ebola vaccine development consortia
Seeking Alpha - at Seeking Alpha - Fri Jan 16, 7:54AM CST
JNJ: 99.62 (+1.18), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), GSK: 47.94 (+1.99)
Critical Alerts For Ford, BlackBerry, Aegerion Pharmaceuticals, Yahoo! and NewLink Genetics Released By InvestorsObserver
PR Newswire - Thu Jan 15, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for F, BBRY, AEGR, YHOO and NLNK.
YHOO: 44.42 (+0.50), F: 16.30 (-0.06), BBRY: 10.09 (+0.23), NLNK: 38.84 (+1.51), AEGR: 25.15 (+0.88)
Affymetrix (AFFX) Expands Genotyping Arrays Product Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 12:10PM CST
Provider of life science tools and molecular diagnostic products, Affymetrix, Inc. (AFFX), is expected to highlight various new genotyping arrays at the 2015 Plant and Animal Genome Conference.
NLNK: 38.84 (+1.51), ALXN: 182.29 (+6.02), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
Biotech Weekly: Lessons Learned From Investing In Ebola Stocks
Daniel Ward - at Seeking Alpha - Mon Jan 12, 7:38AM CST
HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), IBIO: 0.90 (+0.36)
InsiderInsights.com Daily Round Up 1/8/15: CPRX, HCOM, RPXC, ARIS
InsiderInsights - at Seeking Alpha - Sat Jan 10, 2:07AM CST
RH: 86.77 (-1.55), MNST: 117.74 (-1.77), HCOM: 26.76 (-0.10), SPE: 15.27 (+0.02), PGEM: 13.79 (+0.24), ARIS: 3.63 (-0.01), FUND: 7.47 (+0.05), RPXC: 13.94 (+0.42), CMC: 15.40 (+0.37), LNKD: 269.00 (+1.83), PFPT: 55.97 (+0.38), CPRX: 3.36 (-0.10), REN: 1.14 (unch), NERV: 4.68 (+0.09), NLNK: 38.84 (+1.51), CPLA: 65.23 (-1.37), WYY: 1.50 (+0.02), ESP: 29.25 (+2.53)
Biogen Reveals Positive Data from Acute Optic Neuritis Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 4:35PM CST
Biogen Idec (BIIB) announced positive top-line results from a phase II study on anti-LINGO-1 for the treatment of patients suffering from acute optic neuritis.
BIIB: 391.66 (-0.45), NLNK: 38.84 (+1.51), AMAG: 41.49 (+0.23), RGDO: 1.17 (+0.02)
Biotech Investors Guide and Preview to the J.P. Morgan Healthcare Conference Part 2
at The Street - Fri Jan 09, 6:40AM CST
The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.
NLNK: 38.84 (+1.51), JUNO: 40.52 (+0.18), EXAS: 25.56 (-0.54), ABBV: 58.05 (+1.00), MNKD: 7.00 (+0.02)
NewLink Genetics to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 07, 4:00PM CST
NewLink Genetics Corporation (Nasdaq:NLNK) today announced that Charles J. Link, Jr., M.D., NewLink's Founder and Chief Executive Officer, is scheduled to present at the 33 Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 14, 2015 at 4:00 p.m. PT. The presentation will not be webcast.
JPM: 59.67 (+0.10), NLNK: 38.84 (+1.51)
Scotland confirms Ebola case
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 12:53AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22)
NewLink and Merck Get a $30M Contract for Ebola Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 11:00AM CST
NewLink Genetics and Merck announced that the BARDA has awarded a $30 million contract for their Ebola vaccine candidate, rVSV-EBOV.
MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), GSK: 47.94 (+1.99)
Viral Investing: Ebola Drug Makers' Varied Strategies
at Investor's Business Daily - Fri Dec 26, 3:09PM CST
The stock market is an organism that strives to identify opportunity in every crisis. That held true in the late summer and early fall, when the outbreak of Ebola virus in West Africa reached crisis proportions in Guinea, Liberia and Sierra Leone....
BBP: 28.36 (+0.12), INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BBC: 28.98 (+0.18), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), MRK: 58.81 (-0.07), SRPT: 12.76 (+0.11), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), GSK: 47.94 (+1.99)
BARDA awards Ebola vaccine contract to NewLink Genetics
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 7:44AM CST
MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51)
NewLink Genetics, Merck Collaboration to Manufacture Ebola Vaccine Candidate Supported by $30 Million Government Award
GlobeNewswire - Mon Dec 22, 7:00AM CST
NewLink Genetics Corporation (Nasdaq:NLNK) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) has awarded NewLink Genetics' wholly-owned subsidiary, BioProtection Systems, as the prime contractor in a $30 million contract to support the manufacturing and development activities of its investigational rVSV-EBOV (Ebola) vaccine candidate, including clinical development through a new 330-person Phase Ib study.
MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51)
